WHEN it comes to managing patients with lung cancer, smoking status should no longer be the be-all and end-all of the conversation, says an Australian expert.
āWe have to move on from the stigma and bias, be it conscious or unconscious, against lung cancer,ā said Professor Fraser Brims, Deputy Director of the Institute for Respiratory Health, and a consultant respiratory physician at Sir Charles Gairdner Hospital in Perth.
āAs a community, both the lung cancer community and the medical community as a whole, we have to move past this.
āItās not fair to judge individuals by a risk factor. We donāt judge people whoāve had bowel cancer and say, āgoodness, you must have eaten a lot of processed red meat in the pastā. And we shouldnāt be doing the same with lung cancer and smoking because itās not about that anymore.ā
In an exclusive podcast, Professor Brims told InSight+ that about 13 000 people per year were diagnosed with lung cancer in Australia.
āAnd thatās increasing, mostly as a function of our ageing population ā and age is a big driver for just about all cancers, but particularly lung cancer.
āBut the legacy of tobacco smoking, which peaked around the late 1970s and 1980s, is still significant for many Australians,ā he said.
However, one changing aspect of lung cancer in Australia was the increasing rate of never smokers being diagnosed.
āAn important message is that lung cancer is no longer about smokers ā up to one in five patients with lung cancers might never have smoked,ā said Professor Brims.
āThatās got important ramifications for stigma as well as certain treatments and outcomes.ā
A case study and discussion published in the MJA detailed the differences between lung cancer in smokers and that in never smokers:
āThese patients are often diagnosed with advanced and aggressive cases of nonāsmall cell lung cancer (NSCLC), with distinct clinicopathological and molecular features and a higher incidence of targetable mutations compared with lung cancer seen in smokers,ā wrote Dean and colleagues.
āIt is important for [GPs] and general physicians to be aware that NSCLC may present in a diverse manner and, importantly, to consider a differential of NSCLC in young, nonāsmoking patients who present with acute and/or atypical respiratory symptoms.
āChest CT imaging and diagnostic testing should be sought early to avoid delays in diagnosis and to initiate appropriate management.
āWith the availability of effective targeted therapies, patients with lung cancer with a lightā or neverāsmoking history should have comprehensive molecular tissue testing performed on their tumour biopsy to identify potential driver mutations.ā
Are opportunities to diagnose lung cancer early being missed because a patient is a never smoker?
āThere are anecdotal stories of that for sure,ā said Professor Brims told InSight+. āPatients and consumer advocates certainly bear those stories.
āItās important for [doctors] to take that on board ā you canāt ignore a new cough, or a changing cough, even if [that person] has never smoked.
āThatās not the point anymore. Itās the wrong question to ask about lung cancer. Yes, itās an important factor, but there are other equally important factors now as well.ā
Professor Brims is the lead author of an open access Perspective published in the MJA detailing the progress made in the prognosis and treatment of lung cancer.
āThere has been minimal improvement in prognosis over several decades, and the 5āyear survival rate for all lung cancers in Australia is 19%,ā Brims and colleagues wrote.
āAccurate staging for lung cancer is crucial to inform both prognosis and treatment options, but it is complete in only around twoāthirds of cases in Australia and New Zealand. At present, 42% of Australians with NSCLC are diagnosed with stage IV disease, and Australians living in remote and very remote regions are less likely to be diagnosed with stage I disease and have a higher ageāstandardised mortality.ā
Professor Brims told InSight+ that there were improvements to be made in the variation in care across the country.
āThere are certainly areas where improvements could be made,ā he said.
āOne of them is simply access to a multidisciplinary team (MDT). Our research found that five out 79 Australian institutions had no MDT, and yet they were treating lung cancer.
āIn this day and age ā¦ we know from clear data from multiple sources all over the world that accessing MDTs improves accessibility to treatments, accessibility to curative therapy, accessibility to systemic anticancer therapy, and even survival. Thereās a paper recently from the Victorian Lung Cancer Registry team which demonstrated a clear survival benefit when a patient is discussed at an MDT.
āIn Australia in 2022, there should be an expectation that every patient gets discussed at an MDT,ā said Professor Brims.
āEven if theyāre thought to be simple, in inverted commas, there is still a benefit. Thatās something as a lung cancer community we could do with being very clear and resolute about, to improve care for our patients.ā
Governments have their part to pay as well, he said.
āFunders and governments need to take lung cancer more seriously. Thereās an inversely proportional relationship between research funding and the burden of the disease.
āLung cancer as the highest burden of any cancer in Australia, and it has some of the lowest tier one research funding.
āItās unacceptable in this day and age.ā
Online first at the MJA
Perspective: Practical recommendations to communicate with patients about health-related conspiracy theories Marques et al; doi: 10.5694/mja2.51475 ā¦ OPEN ACCESS permanently
Consensus statement summary: Management of type 2 diabetes in young adults aged 18ā30 years: ADS/ADEA/APEG consensus statement Wong et al; doi: 10.5694/mja2.51482 ā¦ FREE ACCESS for one week
Research: Adherence by orthopaedic surgeons to AHPRA and Australian Orthopaedic Association advertising guidelines Ryan et al; doi: 10.5694/mja2.51490 ā¦ FREE ACCESS permanently
āWe have to move on from the stigma and bias, be it conscious or unconscious, against lung cancer,ā said Professor Fraser Brims, Deputy Director of the Institute for Respiratory Health, and a consultant respiratory physician at Sir Charles Gairdner Hospital in Perth.
āAs a community, both the lung cancer community and the medical community as a whole, we have to move past this.
āItās not fair to judge individuals by a risk factor. We donāt judge people whoāve had bowel cancer and say, āgoodness, you must have eaten a lot of processed red meat in the pastā. And we shouldnāt be doing the same with lung cancer and smoking because itās not about that anymore.ā
In an exclusive podcast, Professor Brims told InSight+ that about 13 000 people per year were diagnosed with lung cancer in Australia.
āAnd thatās increasing, mostly as a function of our ageing population ā and age is a big driver for just about all cancers, but particularly lung cancer.
āBut the legacy of tobacco smoking, which peaked around the late 1970s and 1980s, is still significant for many Australians,ā he said.
However, one changing aspect of lung cancer in Australia was the increasing rate of never smokers being diagnosed.
āAn important message is that lung cancer is no longer about smokers ā up to one in five patients with lung cancers might never have smoked,ā said Professor Brims.
āThatās got important ramifications for stigma as well as certain treatments and outcomes.ā
A case study and discussion published in the MJA detailed the differences between lung cancer in smokers and that in never smokers:
āThese patients are often diagnosed with advanced and aggressive cases of nonāsmall cell lung cancer (NSCLC), with distinct clinicopathological and molecular features and a higher incidence of targetable mutations compared with lung cancer seen in smokers,ā wrote Dean and colleagues.
āIt is important for [GPs] and general physicians to be aware that NSCLC may present in a diverse manner and, importantly, to consider a differential of NSCLC in young, nonāsmoking patients who present with acute and/or atypical respiratory symptoms.
āChest CT imaging and diagnostic testing should be sought early to avoid delays in diagnosis and to initiate appropriate management.
āWith the availability of effective targeted therapies, patients with lung cancer with a lightā or neverāsmoking history should have comprehensive molecular tissue testing performed on their tumour biopsy to identify potential driver mutations.ā
Are opportunities to diagnose lung cancer early being missed because a patient is a never smoker?
āThere are anecdotal stories of that for sure,ā said Professor Brims told InSight+. āPatients and consumer advocates certainly bear those stories.
āItās important for [doctors] to take that on board ā you canāt ignore a new cough, or a changing cough, even if [that person] has never smoked.
āThatās not the point anymore. Itās the wrong question to ask about lung cancer. Yes, itās an important factor, but there are other equally important factors now as well.ā
Professor Brims is the lead author of an open access Perspective published in the MJA detailing the progress made in the prognosis and treatment of lung cancer.
āThere has been minimal improvement in prognosis over several decades, and the 5āyear survival rate for all lung cancers in Australia is 19%,ā Brims and colleagues wrote.
āAccurate staging for lung cancer is crucial to inform both prognosis and treatment options, but it is complete in only around twoāthirds of cases in Australia and New Zealand. At present, 42% of Australians with NSCLC are diagnosed with stage IV disease, and Australians living in remote and very remote regions are less likely to be diagnosed with stage I disease and have a higher ageāstandardised mortality.ā
Professor Brims told InSight+ that there were improvements to be made in the variation in care across the country.
āThere are certainly areas where improvements could be made,ā he said.
āOne of them is simply access to a multidisciplinary team (MDT). Our research found that five out 79 Australian institutions had no MDT, and yet they were treating lung cancer.
āIn this day and age ā¦ we know from clear data from multiple sources all over the world that accessing MDTs improves accessibility to treatments, accessibility to curative therapy, accessibility to systemic anticancer therapy, and even survival. Thereās a paper recently from the Victorian Lung Cancer Registry team which demonstrated a clear survival benefit when a patient is discussed at an MDT.
āIn Australia in 2022, there should be an expectation that every patient gets discussed at an MDT,ā said Professor Brims.
āEven if theyāre thought to be simple, in inverted commas, there is still a benefit. Thatās something as a lung cancer community we could do with being very clear and resolute about, to improve care for our patients.ā
Governments have their part to pay as well, he said.
āFunders and governments need to take lung cancer more seriously. Thereās an inversely proportional relationship between research funding and the burden of the disease.
āLung cancer as the highest burden of any cancer in Australia, and it has some of the lowest tier one research funding.
āItās unacceptable in this day and age.ā
Online first at the MJA
Perspective: Practical recommendations to communicate with patients about health-related conspiracy theories Marques et al; doi: 10.5694/mja2.51475 ā¦ OPEN ACCESS permanently
Consensus statement summary: Management of type 2 diabetes in young adults aged 18ā30 years: ADS/ADEA/APEG consensus statement Wong et al; doi: 10.5694/mja2.51482 ā¦ FREE ACCESS for one week
Research: Adherence by orthopaedic surgeons to AHPRA and Australian Orthopaedic Association advertising guidelines Ryan et al; doi: 10.5694/mja2.51490 ā¦ FREE ACCESS permanently
Loading commentsā¦
More from this week
Health policy
18 May 2026
Budget 2026-27 analysis: urgent care, public dental, Aboriginal and Torres Strait Islander health
Indigenous health
18 May 2026
Trachoma successfully eliminated in Australia through Indigenous-led health care
Newsletters
Subscribe to the InSight+ newsletter
Immediate and free access to the latest articles
No spam, you can unsubscribe anytime you want.
By providing your information, you agree to our Access Terms and our Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.